New drug cocktail shows promise for Hard-to-Treat cancers
NCT ID NCT04042701
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and pembrolizumab (an immunotherapy)—in about 115 adults with advanced breast or non-small cell lung cancer that has a specific marker called HER2. The study has two parts: first, finding the safest dose of the combo, and then checking how well it shrinks tumors. Participants must have tried other treatments before and be willing to provide tumor samples.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
trastuzumab deruxtecan (a targeted chemotherapy) and pembrolizumab (an immunotherapy)
What this could lead to
If this combination works, it could offer a new treatment option for people with advanced HER2-positive breast or lung cancer that has stopped responding to other therapies.
What could go wrong
This is an early phase 1 trial with only 115 participants, so it is primarily testing safety and dosing. The combination may cause significant side effects, and it is too soon to know if it will be effective or widely available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de Poitiers
Poitiers, 86000, France
-
CHUTimone
Marseille, 13385, France
-
Cancer Specialists of North Florida (Cbo)
Jacksonville, Florida, 32256, United States
-
Center for Cancer & Blood Disorders
Bethesda, Maryland, 20817, United States
-
Centre Hospitalier Intercommunal de Créteil
Créteil, 94000, France
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Hope Cancer Center of East Texas
Tyler, Texas, 75701, United States
-
Hopital Universitario Insular de Gran Canaria
Las Palmas de Gran Canaria, 35016, Spain
-
Hospital General Univ. Gregorio Marañon
Madrid, 28009, Spain
-
Hospital Teresa Herrera (C.H.U.A.C)
A Coruña, 15006, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Miguel Servet
Zaragoza, 50009, Spain
-
Hospital Universitario Virgen Macarena
Seville, 41009, Spain
-
Hospital de la Santa Creu i de Sant Pau
Barcelona, 08025, Spain
-
Inst. Oncologico Baselga Hospital Quiron
Barcelona, 08023, Spain
-
Institut Bergonie
Bordeaux, 33000, France
-
Institut Gustave Roussy
Villejuif, 94805, France
-
Institut PAOLI-CALMETTES
Marsielle, 13273, France
-
MD Anderson Cancer Center
Madrid, 28033, Spain
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
-
Moffit Cancer Center
Tampa, Florida, 33612, United States
-
Moffitt Cancer Center
Tampa, Florida, 32256, United States
-
Royal Marsden Hosptial
Sutton, SM2 5PT, United Kingdom
-
Sarah Cannon Research Institute (SCRI)
London, W1G 6AD, United Kingdom
-
Siteman Cancer Center-Washington University
St Louis, Missouri, 63110, United States
-
The Christie NHS Fond. Trust
Manchester, M20 4BX, United Kingdom
-
The Royal Marsden NHS Foundation Trust
London, SW3 6JJ, United Kingdom
-
Univ. du Cancer de Toulouse
Toulouse, 31100, France
-
Univ. of Cali. San Francisco Medical Center
San Francisco, California, 94143, United States
-
Yale Cancer Center
New Haven, Connecticut, 06520, United States